Razz Biopharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
- Revenue Growth 74.77%
- Profit Growth 108.73%
- Ebitda 657.28%
- Net Worth 24.42%
- Total Assets 22.33%
About Razz Biopharma
Razz Biopharma Private Limited (RBPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 May 2012 and has a history of 12 years and eight months. Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Satish Pandey and Shiv Tewari serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74120UP2012PTC050690
-
Company No.
050690
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 May 2012
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Razz Biopharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satish Pandey
|
Director | 15-Oct-2018 | Current |
|
Shiv Tewari
|
Director | 15-Oct-2018 | Current |
Financial Performance of Razz Biopharma.
Razz Biopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 74.77% increase. The company also saw a substantial improvement in profitability, with a 108.73% increase in profit. The company's net worth Soared by an impressive increase of 24.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Razz Biopharma?
In 2023, Razz Biopharma had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Faith Formulations LlpSatish Pandey and Shiv Tewari are mutual person
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Jan 2019 | Others | ₹1.00 M | Open |
How Many Employees Work at Razz Biopharma?
Unlock and access historical data on people associated with Razz Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Razz Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Razz Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
